Integrating network pharmacology and in vivo model to reveal the cardiovascular protective effects of kaempferol-3-O-rutinoside on heart failure Cover

.blurhash-client-img { display: none !important; }

Integrating network pharmacology and in vivo model to reveal the cardiovascular protective effects of kaempferol-3-O-rutinoside on heart failure

Acta Pharmaceutica

Volume 75 (2025): Issue 1 (March 2025)

By: Lu-Qin Guo, Lan Zhou, Sheng-Nan Li, Juan Bai, Ling-Li Shi, Fang Hua and Peng Zhou

Open Access

|Apr 2025

Authors

Lu-Qin Guo

Department of Integrated Traditional Chinese and Western Medicine, Anhui University of Chinese Medicine, China

Lan Zhou

Department of Integrated Traditional Chinese and Western Medicine, Anhui University of Chinese Medicine, China

Sheng-Nan Li

School of Pharmacy, Anhui Xinhua University Hefei, Anhui, China

Juan Bai

School of Pharmacy, Anhui Xinhua University Hefei, Anhui, China

Ling-Li Shi

School of Pharmacy, Anhui Xinhua University Hefei, Anhui, China

Fang Hua

happyhf6941@sina.com

School of Pharmacy, Anhui Xinhua University Hefei, Anhui, China

Peng Zhou

zhoupeng@ahtcm.edu.cn

Department of Integrated Traditional Chinese and Western Medicine, Anhui University of Chinese Medicine, China

Research Institute of Integrated Traditional Chinese and Western Medicine, Anhui Academy of Chinese Medicine, China

Anhui Provincial Key Laboratory of Chinese Medicinal Formula, China

DOI: https://doi.org/10.2478/acph-2025-0001 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075

Journal RSS Feed

Language: English

Page range: 119 - 132

Accepted on: Nov 12, 2024

|

Published on: Apr 10, 2025

Published by: Croatian Pharmaceutical Society

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

network pharmacology,

kaempferol-3--rutinoside,

molecular docking,

Related subjects:

Pharmacy, other

© 2025 Lu-Qin Guo, Lan Zhou, Sheng-Nan Li, Juan Bai, Ling-Li Shi, Fang Hua, Peng Zhou, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous article Volume 75 (2025): Issue 1 (March 2025)Next article